Matricelf

Company Overview

Snapshot

Founded in April 2019 by Alon Sinai, Matricelf operates with 11–50 employees. The company has raised $10.04M across four funding rounds from two investors. Matricelf became publicly listed on the TASE in June 2021, marking a significant milestone in its development.

Business overview

Matricelf is a Health Tech & Life Sciences company specializing in personalized autologous regenerative medicine. The company has developed a technology for producing engineered tissue from a patient's own omental biopsies, which includes separating stromal cells and extracellular matrix (ECM) to create a thermo-responsive hydrogel. This hydrogel, combined with reprogrammed induced pluripotent stem cells (iPSCs), is differentiated into desired functional tissue. Matricelf's platform aims to treat various medical conditions, including spinal cord injuries, age-related macular degeneration, and Parkinson's disease, serving the healthcare and life sciences sectors.

Strategic signal

In June 2026, Matricelf initiated an IND-enabling efficacy study following positive preclinical results for spinal cord injury, alongside advancing towards its first-in-human trial with the initiation of a GMP manufacturing program and successful GLP safety study completion. This signals a strong progression towards clinical validation and commercialization of its personalized regenerative therapies, indicating significant de-risking and potential for future therapeutic breakthroughs.

Company Intelligence Q&A

What is Matricelf's core technology?

Matricelf's core technology involves producing autologous engineered tissue from a patient's omental biopsies. This process separates stromal cells and extracellular matrix (ECM) to create a thermo-responsive hydrogel, which is then combined with reprogrammed induced pluripotent stem cells (iPSCs) to differentiate into functional tissue for regenerative medicine applications.

When did Matricelf become a public company?

Matricelf became publicly listed on the TASE in June 2021.

What was a key strategic collaboration for Matricelf in March 2026?

In March 2026, Matricelf entered a strategic collaboration with Japan's CiRA Foundation to advance next-generation regenerative manufacturing, aiming to enhance its capabilities in personalized therapies.

What recent progress has Matricelf made in its spinal cord injury program?

In June 2026, Matricelf initiated an IND-enabling efficacy study following positive preclinical results in spinal cord injury. This advancement builds on successful GLP safety study completion and the initiation of a GMP manufacturing program, moving the company closer to its first-in-human trial.

What leadership change occurred at Matricelf in February 2026?

In February 2026, Matricelf appointed Ron Mayron as Chairman of the Board.